26-05-2025
Rizatriptan Disappoints for Acute Vestibular Migraine
Rizatriptan at 10 mg showed no significant benefit over placebo in alleviating vertigo or unsteadiness/dizziness at 1 hour in adults with vestibular migraine in a new trial. The drug showed limited benefits for unsteadiness/dizziness and motion sensitivity at 24 hours with medium effect sizes. METHODOLOGY: This double-blind randomized clinical trial conducted from 2014 to 2020 at two tertiary neurotologic centers included 222 adults with vestibular migraine (mean age, 42.3 years; 71% women).
After a prospective observation phase to confirm diagnosis, participants were randomly assigned (2:1) to receive 10 mg rizatriptan or placebo to treat up to three vestibular migraine attacks per participant with a single oral dose.
The primary outcome measure was the percentage of treated attacks with vertigo and unsteadiness/dizziness alleviated from moderate or severe to absent or mild at 1 hour.
Secondary outcomes included the complete resolution of vestibular symptoms and alleviation of headache and associated symptoms at 1 hour, use of rescue medications after 1 hour, alleviation of symptoms at 24 hours, treatment satisfaction and adverse effects at 48 hours. TAKEAWAY: The analysis of 240 attacks with moderate or severe vestibular symptoms showed that rizatriptan did not outperform placebo for vertigo (odds ratio [OR], 0.69; 95% CI, 0.33-1.46) or unsteadiness/dizziness (OR, 1.86; 95% CI, 0.75-4.62) at 1 hour.
The use of rescue medication was identical at 26.4% between groups, with rizatriptan showing medium effects over placebo for unsteadiness/dizziness (OR, 2.65; 95% CI, 1.04-6.79), photophobia or phonophobia (OR, 2.77; 95% CI, 1.00-7.77), and motion sensitivity (OR, 3.58; 95% CI, 1.44-8.88) at 24 hours.
Treatment satisfaction and quality-of-life outcomes at 48 hours showed mixed results.
Adverse events were not significantly different between groups. No serious adverse events were reported. IN PRACTICE:
'Results of this study do not support routine use of rizatriptan to treat vestibular migraine attacks. It was not efficacious for any symptoms at 1 hour and demonstrated no effects on vertigo,' the investigators wrote. SOURCE:
The study was led by Jeffrey P. Staab, MD, MS, Mayo Clinic, Rochester, Minnesota. It was published online on May 12 in JAMA Neurology . LIMITATIONS:
The findings were not generalizable to community or primary care settings. The cohort represented a small subset of referred patients who met strict diagnostic criteria, excluding those with probable vestibular migraine. DISCLOSURES:
This study was funded by the National Institute of Deafness and Other Communication Disorders. One investigator reported receiving royalties for co-authoring a chapter on vestibular migraine for UpToDate.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Credit
Lead image: Noipornpan/Dreamstime
Medscape Medical News © 2025 WebMD, LLC
Cite this: Rizatriptan Disappoints for Acute Vestibular Migraine - Medscape - May 26, 2025.
